ERJ Podcast February 2026: Addressing the global challenges of COPD and asthma
ERS Publications PodcastsShow Notes
As part of the February issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews David Halpin (University of Exeter Medical School, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK) about his Viewpoint editorial on a shared vision from the Global Initiative for Chronic Obstructive Lung Disease and the Global Initiative for Asthma of how to address the global challenges of COPD and asthma, published in this issue of the ERJ (https://doi.org/10.1183/13993003.02244-2025).
Cite this podcast as: ERJ Podcast February 2026: Addressing the global challenges of COPD and asthma. Eur Respir J 2026; 67: 26E6702 [https://doi.org/10.1183/13993003.E6702-2026].
More from ERS Publications Podcasts
"We [should] not only focus on one treatment option but we should discuss how we can combine different options; this has to be studied in more detail"
As part of the September issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers interviews editorial board member Christina Thornton and associate editor Marcus Mall about their Back to Basics review article on bridging the airway microbiome and targeted therapy in bronchiectasis, published in this issue of the ERJ (https://doi.org/10.1183/13993003.00239-2026).
As part of the August issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews Marlies van Dijk (University of Groningen, Groningen, The Netherlands) about her multicentre randomised crossover trial of fentanyl and morphine for persistent dyspnoea in COPD, published in this issue of the ERJ (https://doi.org/10.1183/13993003.01431-2025).
As part of the July issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers interviews Associate Editor Marlies Wijsenbeek about data from the whole follow-up period of the FIBRONEER-ILD trial of nerandomilast in progressive pulmonary fibrosis, published in this issue of the ERJ (https://doi.org/10.1183/13993003.01272-2025).
"Making ultrasound as widespread and as used as the stethoscope... that's the big challenge going forwards"